13F-HR filed by Remedium Capital Partners, LLC
Remedium Capital Partners, LLC filed this 13F-HR for the quarter ended 2026-06-30, filed 2026-08-07, with 6 holding rows worth $451,627,235.
- Accession
- 0002104501-26-000015
- Filer
- CIK 2104501
- Filed
- 2026-08-07
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2026
A holdings report, 6 entries on the cover page, a total value of $451,627,235 stated on the cover page (in dollars after the unit check, H1), rows summing to $451,627,235 with VALUE read as dollars as filed, 13F file number 028-26277. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ORUKA THERAPEUTICS INC COM | 687604108 | Stock | 1,565,661 | $149,003,957 | dollars as filed | |
| SPYRE THERAPEUTICS INC | 00773J202 | COM NEW | 1,464,169 | $129,988,924 | dollars as filed | |
| APOGEE THERAPEUTICS INC COM | 03770N101 | Stock | 586,691 | $77,871,496 | dollars as filed | |
| DAMORA THERAPEUTICS INC | 36322Q206 | COMMON STOCK | 2,045,473 | $53,202,753 | dollars as filed | |
| JADE BIOSCIENCES INC | 008064206 | COM NEW | 1,577,750 | $35,057,605 | dollars as filed | |
| CRESCENT BIOPHARMA INC | G2545C104 | COMMON STOCK | 361,250 | $6,502,500 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0002104501-26-000015 | this filing | 2026-08-07 | acceptance time not in the bulk data set |